IOVA Posts Record $99.3M Q2 as Amtagvi Launch Accelerates

Iovance Biotherapeutics (IOVA) posted record second-quarter 2026 revenue of $99.3 million, crushing its own guidance of $86-88 million and beating the $94 million consensus estimate. The number represents 66% growth year-over-year and 39% sequential growth from Q1, driven almost entirely by Amtagvi, the first FDA-approved tumor-infiltrating lymphocyte (TIL) cell therapy for advanced melanoma.

IOVA closed at $6.34 before the August 6 earnings release, then surged 43% on the beat. Volume hit roughly 31 million shares against a normal daily average well below that. The stock remains well off its 2024 highs above $18, but this quarter materially changed the commercial narrative.

The Amtagvi ramp is real

Amtagvi product revenue came in at roughly $91 million of the $99.3 million total, with the balance from Proleukin (aldesleukin), which is administered alongside TIL therapy as part of the treatment regimen. Gross margin reached 56%, up from roughly 34% a year ago, as manufacturing scale absorbed fixed costs and the internal Proleukin supply chain matured.

The company ended the quarter with $303.7 million in cash and a net loss of $47.3 million, or $0.11 per share, narrowed from $0.33 per share a year earlier. Iovance is reviewing its full-year 2026 revenue guidance of $350-370 million and will provide an update in Q3.

Why this quarter matters

The bear case on Iovance has always been that TIL therapy cannot scale. Each dose requires harvesting a patient’s tumor, expanding the infiltrating lymphocytes in a lab over roughly 22 days, then reinfusing them, a logistics chain far more complex than off-the-shelf checkpoint inhibitors. A 39% sequential revenue jump with expanding gross margins suggests the operational bottlenecks are being resolved, not compounding.

The addressable market is roughly 10,000-12,000 US patients per year with anti-PD-1-refractory advanced melanoma. Amtagvi is under 5% penetrated. The next catalysts are a melanoma data update at ESMO in September and a planned BLA submission for non-small cell lung cancer, which would roughly triple the addressable patient population if approved. Iovance also reported early progress on a next-generation TIL manufacturing process that could cut the vein-to-vein time below 16 days.

The risk is execution. Amtagvi’s commercial trajectory depends on expanding authorized treatment centers, currently around 50, and maintaining the gross margin gains as volume grows. Any manufacturing failure rate increase or treatment center saturation would compress the growth curve. The ESMO data and NSCLC filing are the near-term events to watch.

For more on the FDA approval pathway that brought Amtagvi to market, see the guide to PDUFA dates.

Source: Iovance Q2 2026 earnings release